Document is current
Any future updates will be listed below
-
Authors
Martin, Alexandra L.
Powell, Chase
Nagy, Mate Z.
Innamarato, Patrick
Powers, John
Nichols, Derek
Anadon, Carmen M.
Chaurio, Ricardo A.
Kim, Sungjune
Wang, Min-hsuan
Gong, Bing
Wang, Xianzhe
Scheutz, Thomas J.
Antonia, Scott J.
Conejo-Garcia, Jose R.
Perez, Bradford A.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA124515, 5K08CA231454)
- License Information
-
More Information
Article History
Received: 15 June 2022
Accepted: 2 November 2022
First Online: 5 December 2022
Declarations
:
: B.A.P has research funding (Bristol Myers Squibb) and has served on advisory board (AstraZeneca, G1 Therapeutics); all outside the submitted work. S. J. A. has served on advisory boards for Bristol Myers Squibb, Celsius, Merck, Samyang Biopharma, AstraZeneca/Medimmune; Consultant: Bristol Myers Squibb, Celsius, Merck, Samyang Biopharma, AstraZeneca/Medimmune, CBMG, Memgen, RAPT, Venn, Achilles Therapeutics, GlaxoSmithKline, Amgen; Scientific advisory board: CBMG, Memgen, RAPT, Venn, Achilles Therapeutics, GlaxoSmithKline, Amgen. J.R.C.G. has stock options in Compass Therapeutics, Anixa Biosciences and Alloy Therapeutics. He also receives consulting fees from Leidos, Alloy Therapeutics and Radyus Research; has sponsored research with Anixa Biosciences; and patent applications with Compass Therapeutics and Anixa Biosciences; all outside the submitted work.
: Animals for this study were maintained by the Moffitt Cancer Center animal facility according to the Association for Assessment and Accreditation of Laboratory Animal Care and National Institute of Health (NIH) standards. All experiments were conducted according to protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the University of South Florida.
: Informed consent was obtained from all individual participants included in the study.
